New Insights into Postpartum Depression Through Brain Imaging Research#USA#Costa_Mesa#Amen_Clinics#postpartum_depression#Brain_Imaging
New Insights into Postpartum Depression Through Brain Imaging Research
Recent research from Amen Clinics reveals significant brain function differences between postpartum depression and major depression, highlighting the need for tailored treatments.
third-news.com
October 2, 2026 at 9:07 AM
New Insights into Postpartum Depression Through Brain Imaging Research#USA#Costa_Mesa#Amen_Clinics#postpartum_depression#Brain_Imaging
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression
Lipocine has announced the initiation of the BLOOM Phase 3 study for LPCN 1154, targeting postpartum depression treatment with promising oral therapies.
third-news.com
September 14, 2026 at 12:17 PM
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
The Future of Postpartum Depression Treatments: Emerging Trends and Opportunities (2026-2036)#None#LPCN_1154#postpartum_depression#Luvesilocin
The Future of Postpartum Depression Treatments: Emerging Trends and Opportunities (2026-2036)
As awareness and treatment options for postpartum depression grow, innovative therapies promising rapid relief are emerging, reshaping the market landscape.
third-news.com
August 25, 2026 at 2:35 PM
The Future of Postpartum Depression Treatments: Emerging Trends and Opportunities (2026-2036)#None#LPCN_1154#postpartum_depression#Luvesilocin
Los Angeles Hosts Major Conference Focused on Perinatal Mental Health Issues and Solutions#United_States#Los_Angeles#postpartum_depression#Postpartum_Support_International#Perinatal_Mental_Health
Los Angeles Hosts Major Conference Focused on Perinatal Mental Health Issues and Solutions
The world's largest perinatal mental health conference kicks off this week in Los Angeles, aiming to elevate awareness and offer solutions for mental health challenges like postpartum depression.
third-news.com
June 22, 2026 at 12:23 PM
Los Angeles Hosts Major Conference Focused on Perinatal Mental Health Issues and Solutions#United_States#Los_Angeles#postpartum_depression#Postpartum_Support_International#Perinatal_Mental_Health
Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial
Lipocine Inc.'s Phase 3 trial results for LPCN 1154 in postpartum depression reveal mixed efficacy and a well-tolerated safety profile among participants.
third-news.com
April 2, 2026 at 12:42 PM
Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Long-Term Benefits of mHealth Consultation on Postpartum Depression#Japan#Yokohama#postpartum_depression#Yokohama_City#mHealth_Consultation
Long-Term Benefits of mHealth Consultation on Postpartum Depression
A recent study highlights significant long-term benefits of online healthcare consultations in reducing postpartum depression risks by 32%.
third-news.com
March 4, 2026 at 4:51 AM
Long-Term Benefits of mHealth Consultation on Postpartum Depression#Japan#Yokohama#postpartum_depression#Yokohama_City#mHealth_Consultation
Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment
Lipocine Inc. completes the last patient visit in the Phase 3 trial of LPCN 1154, an oral treatment for postpartum depression (PPD), showing positive safety results.
third-news.com
February 18, 2026 at 1:22 PM
Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression
Lipocine has finished participant enrollment and dosing in its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression. Initial results are promising.
third-news.com
January 20, 2026 at 1:39 PM
Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review
Lipocine Inc. announced the successful completion of an independent safety review for LPCN 1154 in a Phase 3 trial targeting postpartum depression, reinforcing confidence in its efficacy.
third-news.com
January 12, 2026 at 1:14 PM
Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression
Lipocine Inc. shares an update on its Phase 3 trial of LPCN 1154 for postpartum depression, with promising enrollment and safety review plans.
third-news.com
September 30, 2025 at 12:18 PM
Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025
Join Lipocine's virtual R&D investor event on July 9, 2025, to explore LPCN 1154's potential in treating postpartum depression, alongside expert insights.
third-news.com
June 23, 2025 at 12:22 PM
Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression
Lipocine Inc. has launched a Phase 3 trial for LPCN 1154, aimed at treating postpartum depression through effective oral delivery.
third-news.com
March 26, 2025 at 12:33 PM
Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Stork Club Unveils Pioneering Care for Postpartum Depression to Aid Working Mothers#United_States#San_Francisco#Stork_Club#working_mothers#postpartum_depression
Stork Club Unveils Pioneering Care for Postpartum Depression to Aid Working Mothers
Stork Club has launched an innovative digital program addressing postpartum depression, offering vital support for working mothers and improving workplace conditions.
third-news.com
February 25, 2025 at 2:59 PM
Stork Club Unveils Pioneering Care for Postpartum Depression to Aid Working Mothers#United_States#San_Francisco#Stork_Club#working_mothers#postpartum_depression
Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression
Lipocine's latest regulatory guidance suggests further safety and efficacy trials for LPCN 1154, aiming to address postpartum depression in women rapidly.
third-news.com
February 6, 2025 at 1:07 PM
Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression